Regeneron CEO Leonard Schleifer elaborated on the biotech company's latest ventures with CNBC's Jim Cramer on Tuesday and emphasized the importance of genetic research across the industry."The big thing for everybody these days is AI, that's the next big thing. But I don't believe that," Schleifer said. "It's a good tool. But for our business, the really, most important tool, I think, is genetics, it's genes."Schleifer suggested that "associating genes with disease" is going to drive the pharmaceutical indu ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) declined 1.13% after the company reported disappointing fourth-quarter preliminary sales for lead drug, Eylea.Sales of Eylea (aflibercept) and Eylea HD (higher dose of Eylea) came in at $1.46 billion in the United States. The Zacks Consensus Estimate for the same was $1.45 billion.Eylea sales came in at $1.34 billion in the United States and Eylea HD sales came in at $123 million in the fourth quarter of 2023. This was the first full quarter for Eylea HD foll ...

Regeneron Pharmaceuticals Inc. - Key Takeaways from the 42nd Annual JPMorgan Healthcare Conference Call Company Overview - **Company**: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) - **Date**: January 8, 2024 - **Participants**: Leonard Schleifer (CEO), George Yancopoulos (CSO), Marion McCourt (EVP, Commercial) Core Industry Insights 2023 Performance Highlights - 2023 was a successful year with significant progress in both core products and pipeline development [2][5] - Key products include EYLEA and DUPIXENT, with EYLEA HD launched in August 2023 [5][7] - DUPIXENT achieved approximately $8.4 billion in sales in the first nine months of 2023, reflecting a 34% growth [8][9] EYLEA HD Launch - EYLEA HD generated $123 million in its first quarter, indicating strong market acceptance despite some prescriber hesitancy due to lack of a permanent J-code [7][8] - Approximately two-thirds of lives are covered, and a permanent J-code is expected to enhance reimbursement confidence by April 2024 [8][36] DUPIXENT Developments - DUPIXENT has been approved for five indications and is expected to launch for COPD, targeting approximately 500,000 patients in the G7 [10][20] - The product has shown a remarkable safety profile and efficacy across various allergic diseases [9][21] Pipeline and Innovation Oncology Pipeline - Regeneron is focusing on immuno-oncology, with three validated classes of immunomodulatory agents [14][15] - The company aims to be a leading oncology player by the end of the decade, with significant advancements in bispecific antibodies [10][15] - Upcoming pivotal data expected from ongoing trials, particularly in melanoma and multiple myeloma [17][57] Genetic Medicines - Regeneron is advancing genetic medicine initiatives, including CRISPR and siRNA technologies, with several programs entering clinical trials [26][27] - The collaboration with Alnylam has achieved proof-of-concept for silencing genes in the liver and brain [26] Obesity and Muscle Preservation - Regeneron is developing antibodies to improve weight loss quality by preserving muscle mass during caloric restriction [24][25] - Early data shows promising results in preclinical models, with trials expected to initiate soon [25] Future Opportunities Severe Allergies - A novel combination approach using DUPIXENT and BCMA bispecific is being explored to potentially reverse severe allergies [21][22] - Clinical trials are planned to assess the safety and efficacy of this combination [52] COPD and Other Indications - The company is preparing for the launch of DUPIXENT for eosinophilic COPD, with strong enthusiasm from pulmonologists [44][46] - Itepekimab, an IL-33 antibody, is also in development for a distinct subset of COPD patients [20] Conclusion - Regeneron is positioned for continued growth with a robust pipeline and innovative approaches across various therapeutic areas, including oncology, genetic medicine, and immunology [12][32] - The company emphasizes its commitment to scientific innovation and improving patient outcomes while maintaining a focus on corporate responsibility [32]

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 42nd Annual JPMorgan Healthcare Conference Call January 8, 2024 5:15 PM ET Company Participants Chris Schott - JPMorgan Leonard Schleifer - Board Co-Chair, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Regeneron today. Fro ...

SolStock/E+ via Getty Images Investment Overview Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), the Tarrytown, New York State-based Pharma company, have been rising sharply in recent months, from $725 in mid-August 2023, to >$910 at the time of writing - up >25%. Regeneron's share float is only just over 100m, and its market cap valuation currently hovers around the $100bn mark. Arguably, that is a generous valuation for a company that has generated top line revenues of $6.6bn, $8.5bn, $16.1bn, an ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...

Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for various indications Medison and Regeneron will work together to continue patient access to this important therapy in select markets ZUG, Switzerland, Jan. 8, 2024 /PRNewswire/ -- Medis ...

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the  ‘Investors and Media' page of Regeneron's ...

Regeneron (REGN) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this biopharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimat ...

Regeneron (REGN) shares rallied 3% in the last trading session to close at $905. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.7% gain over the past four weeks.The going has been good for Regeneron post the FDA approval of higher dose of its lead opthalmology drug Eylea. Regeneron recently won a lawsuit against Viatris for a proposed biosimilar of Eylea, which in turn wards off any biosimilar competition ...